🔎 Trials Near Me

Почетна › Немалоклетни карцином плућа › Misuri

Kliničke studije za Немалоклетни карцином плућа u državi Misuri

83 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u državi Misuri.

Gradovi u državi Misuri

Zvanični tekst studije (na engleskom)

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

  • Washington University School of Medicine, St Louis
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07100080

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Saint Luke's Hospital of Kansas City, Kansas City
  • Saint Luke's East Hospital, Lee's Summit
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06758401

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
  • University Health Truman Medical Center, Kansas City
  • Mercy Hospital South, St Louis
  • и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06498635

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
  • Saint Francis Medical Center, Cape Girardeau
  • Saint Luke's Hospital, Chesterfield
  • и још 18
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04267848

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • Washington University Medicine, St Louis
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06270706

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  • Truman Medical Center ( Site 0126), Kansas City
  • Cox Medical Center North ( Site 0133), Springfield
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06345729

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  • Washington University School of Medicine, St Louis
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07020221

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  • Mercy South - David M Sindelar Cancer Center ( Site 0098), St Louis
  • Mercy Research - David C. Pratt Cancer Center ( Site 0006), St Louis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06312137

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  • Washington University School Of Medicine, St Louis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07680790

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  • Research Site, Bridgeton
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07291037

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  • Luminis Health Radiation Oncology - Anne Arundel Health System, Annapolis
  • University of Kansas Cancer Center - North, Kansas City
  • University of Kansas Cancer Center - Lee's Summit, Lee's Summit
  • и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06216301

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  • Washington University School of Medicine ( Site 3279), St Louis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07513376

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  • Local Institution - 0498, Kansas City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06561386

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Washington University in St. Louis School of Medicine, St Louis
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT04198766

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  • Missouri Cancer Associates, Columbia
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07144280

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

  • Saint Francis Medical Center, Cape Girardeau
  • University of Kansas Cancer Center - Briarcliff, Kansas City
  • University of Kansas Cancer Center - North, Kansas City
  • и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07388524

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  • Missouri Baptist Medical Center, St Louis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06793215

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  • Missouri Cancer Associates, Columbia
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07361497

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • Washington University School of Medicine in St. Louis, St Louis
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06465069

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • Missouri Baptist Medical Center, St Louis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06890598

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
  • Saint Louis Cancer and Breast Institute-Ballwin, Ballwin
  • Parkland Health Center - Farmington, Farmington
  • и још 16
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Oncology Hematology Associates, Springfield
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06119581

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

  • Siteman Cancer Center, St Louis
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07397338

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Truman Medical Ctr West, Kansas City
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06667076

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
  • Central Care Cancer Center - Bolivar, Bolivar
  • Cox Cancer Center Branson, Branson
  • и још 18
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT03191149

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

  • Washington University Medical Campus, St Louis
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT05856981

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

  • Washington University School Of Medicine, St Louis
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT05498428

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  • Saint Francis Medical Center, Cape Girardeau
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07293247

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

  • Washington University in St Louis, St Louis
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06667908

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  • Missouri Cancer Associates, Columbia
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT06712316

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

  • Oncology Hematology Associates, Springfield
  • Barnes-Jewish Hospital - Siteman Cancer Center (Washington University - St. Louis), St Louis
Тражи се учесникФаза 3
Узраст од 18 до 90 · Оба пола · Ажурирано 2. 11. 2026. · NCT06745908

Study of XB010 in Subjects With Solid Tumors

  • Siteman Cancer Center, St Louis
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT06545331

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  • Research Site, Bridgeton
  • Research Site, Kansas City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06692738

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  • St. Lukes Hosp. of Kansas City /ID# 259940, Kansas City
  • Hulston Cancer Center /ID# 232226, Springfield
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT04928846

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

  • Washington University School of Medicine, St Louis
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT07094204

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • Washington University, Siteman Cancer Center, St Louis
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06774963

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  • Research Site, Kansas City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06357533

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  • SSM Health Cancer Care - Fenton, Fenton
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06875310

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

  • Research Site, St Louis
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06835569

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • Washington University, St Louis
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT04981119

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.